Chadi Nabhan, MD, MBA, FACP

Column
Prognostication and Treatment of Diffuse Large B-cell Lymphoma
12/05/2018
Journal of Clinical Pathways is pleased to present a new section called “CME Corner,” which will highlight, when available, relevant continuing medical education (CME) opportunities deemed to be of use to readers....
Journal of Clinical Pathways is pleased to present a new section called “CME Corner,” which will highlight, when available, relevant continuing medical education (CME) opportunities deemed to be of use to readers....
...
12/05/2018
Journal of Clinical Pathways
Research Reports
Community Oncologists` Perception and Acceptance of Biosimilars in Oncology
09/13/2018
Abstract: Biosimilars are hypothesized to contribute to lowering health care costs by entering the market at a discounted price compared with their reference biologics. Until recently, only filgrastim biosimilars...
Abstract: Biosimilars are hypothesized to contribute to lowering health care costs by entering the market at a discounted price compared with their reference biologics. Until recently, only filgrastim biosimilars...
...
09/13/2018
Journal of Clinical Pathways
Counterpoint
CAR-T Therapies: Placing Patient Safety First
08/22/2018
The commercial success and ability of eligible patients to receive chimeric antigen receptor T-cell (CAR-T) therapies depend on optimizing the logistics of delivering this transformational treatment platform. One...
The commercial success and ability of eligible patients to receive chimeric antigen receptor T-cell (CAR-T) therapies depend on optimizing the logistics of delivering this transformational treatment platform. One...
The...
08/22/2018
Journal of Clinical Pathways
Research Reports
Community Oncologists‚ Perception and Adaptability to Emerging Chimeric Antigen T-Cell Therapy
10/16/2017
Abstract: The Oncologic Drugs Advisory Committee recently voted 10-0 recommending to the Food and Drug Administration (FDA) the approval of the first chimeric antigen receptor T (CAR-T) therapy. We sought to better...
Abstract: The Oncologic Drugs Advisory Committee recently voted 10-0 recommending to the Food and Drug Administration (FDA) the approval of the first chimeric antigen receptor T (CAR-T) therapy. We sought to better...
...
10/16/2017
Journal of Clinical Pathways
Feature
Positioning CAR-T Therapy Into Clinical Pathways for Non-Hodgkin B-Cell Lymphoma and Beyond
03/23/2017
Abstract: Enthusiasm for immunotherapy has spread throughout the oncology community in recent years, as therapies harnessing the body’s ability to fight cancers have offered the potential for remission and even cure...
Abstract: Enthusiasm for immunotherapy has spread throughout the oncology community in recent years, as therapies harnessing the body’s ability to fight cancers have offered the potential for remission and even cure...
...
03/23/2017
Journal of Clinical Pathways

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use